FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2176471040> ?p ?o ?g. }

• W2176471040 abstract "As of September 30, 2015, a total of 1589 laboratory-confirmed cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported to the World Health Organization (WHO). At present there is no effective specific therapy against MERS-CoV. The use of convalescent plasma (CP) has been suggested as a potential therapy based on existing evidence from other viral infections. We aim to study the feasibility of CP therapy as well as its safety and clinical and laboratory effects in critically ill patients with MERS-CoV infection. We will also examine the pharmacokinetics of the MERS-CoV antibody response and viral load over the course of MERS-CoV infection. This study will inform a future randomized controlled trial that will examine the efficacy of CP therapy for MERS-CoV infection. In the CP collection phase, potential donors will be tested by the enzyme linked immunosorbent assay (ELISA) and the indirect fluorescent antibody (IFA) techniques for the presence of anti-MERS-CoV antibodies. Subjects with anti-MERS-CoV IFA titer of ≥1:160 and no clinical or laboratory evidence of MERS-CoV infection will be screened for eligibility for plasma donation according to standard donation criteria. In the CP therapy phase, 20 consecutive critically ill patients admitted to intensive care unit with laboratory-confirmed MERS-CoV infection will be enrolled and each will receive 2 units of CP. Post enrollment, patients will be followed for clinical and laboratory outcomes that include anti-MERS-CoV antibodies and viral load. This protocol was developed collaboratively by King Abdullah International Medical Research Center (KAIMRC), Gulf Cooperation Council (GCC) Infection Control Center Group and the World Health Organization—International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC-WHO) MERS-CoV Working Group. It was approved in June 2014 by the Ministry of the National Guard Health Affairs Institutional Review Board (IRB). A data safety monitoring board (DSMB) was formulated. The study is registered at http://www.clinicaltrials.gov (NCT02190799)." @default.
• W2176471040 created "2016-06-24" @default.
• W2176471040 creator A5007698650 @default.
• W2176471040 creator A5010131062 @default.
• W2176471040 creator A5017663434 @default.
• W2176471040 creator A5023631071 @default.
• W2176471040 creator A5026182461 @default.
• W2176471040 creator A5028653219 @default.
• W2176471040 creator A5031318889 @default.
• W2176471040 creator A5032799558 @default.
• W2176471040 creator A5035524531 @default.
• W2176471040 creator A5045066803 @default.
• W2176471040 creator A5052964435 @default.
• W2176471040 creator A5055942371 @default.
• W2176471040 creator A5061407674 @default.
• W2176471040 creator A5062294816 @default.
• W2176471040 creator A5067036149 @default.
• W2176471040 creator A5069499299 @default.
• W2176471040 creator A5072388444 @default.
• W2176471040 creator A5074380996 @default.
• W2176471040 creator A5074778109 @default.
• W2176471040 creator A5075457219 @default.
• W2176471040 creator A5083488106 @default.
• W2176471040 creator A5089509555 @default.
• W2176471040 creator A5090111367 @default.
• W2176471040 date "2015-11-19" @default.
• W2176471040 modified "2023-10-16" @default.
• W2176471040 title "Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol" @default.
• W2176471040 cites W1964402677 @default.
• W2176471040 cites W2057439500 @default.
• W2176471040 cites W2096238447 @default.
• W2176471040 cites W2099941783 @default.
• W2176471040 cites W2108756402 @default.
• W2176471040 cites W2133701960 @default.
• W2176471040 cites W2137591261 @default.
• W2176471040 cites W2148822770 @default.
• W2176471040 cites W2166867592 @default.
• W2176471040 cites W2169659972 @default.
• W2176471040 doi "https://doi.org/10.1186/s40064-015-1490-9" @default.
• W2176471040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4653124" @default.
• W2176471040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26618098" @default.
• W2176471040 hasPublicationYear "2015" @default.
• W2176471040 type Work @default.
• W2176471040 sameAs 2176471040 @default.
• W2176471040 citedByCount "157" @default.
• W2176471040 countsByYear W21764710402016 @default.
• W2176471040 countsByYear W21764710402017 @default.
• W2176471040 countsByYear W21764710402018 @default.
• W2176471040 countsByYear W21764710402019 @default.
• W2176471040 countsByYear W21764710402020 @default.
• W2176471040 countsByYear W21764710402021 @default.
• W2176471040 countsByYear W21764710402022 @default.
• W2176471040 countsByYear W21764710402023 @default.
• W2176471040 crossrefType "journal-article" @default.
• W2176471040 hasAuthorship W2176471040A5007698650 @default.
• W2176471040 hasAuthorship W2176471040A5010131062 @default.
• W2176471040 hasAuthorship W2176471040A5017663434 @default.
• W2176471040 hasAuthorship W2176471040A5023631071 @default.
• W2176471040 hasAuthorship W2176471040A5026182461 @default.
• W2176471040 hasAuthorship W2176471040A5028653219 @default.
• W2176471040 hasAuthorship W2176471040A5031318889 @default.
• W2176471040 hasAuthorship W2176471040A5032799558 @default.
• W2176471040 hasAuthorship W2176471040A5035524531 @default.
• W2176471040 hasAuthorship W2176471040A5045066803 @default.
• W2176471040 hasAuthorship W2176471040A5052964435 @default.
• W2176471040 hasAuthorship W2176471040A5055942371 @default.
• W2176471040 hasAuthorship W2176471040A5061407674 @default.
• W2176471040 hasAuthorship W2176471040A5062294816 @default.
• W2176471040 hasAuthorship W2176471040A5067036149 @default.
• W2176471040 hasAuthorship W2176471040A5069499299 @default.
• W2176471040 hasAuthorship W2176471040A5072388444 @default.
• W2176471040 hasAuthorship W2176471040A5074380996 @default.
• W2176471040 hasAuthorship W2176471040A5074778109 @default.
• W2176471040 hasAuthorship W2176471040A5075457219 @default.
• W2176471040 hasAuthorship W2176471040A5083488106 @default.
• W2176471040 hasAuthorship W2176471040A5089509555 @default.
• W2176471040 hasAuthorship W2176471040A5090111367 @default.
• W2176471040 hasBestOaLocation W21764710401 @default.
• W2176471040 hasConcept C126322002 @default.
• W2176471040 hasConcept C142462285 @default.
• W2176471040 hasConcept C159654299 @default.
• W2176471040 hasConcept C177713679 @default.
• W2176471040 hasConcept C203014093 @default.
• W2176471040 hasConcept C2522874641 @default.
• W2176471040 hasConcept C2776525042 @default.
• W2176471040 hasConcept C2777691041 @default.
• W2176471040 hasConcept C2779134260 @default.
• W2176471040 hasConcept C3008058167 @default.
• W2176471040 hasConcept C524204448 @default.
• W2176471040 hasConcept C535046627 @default.
• W2176471040 hasConcept C71924100 @default.
• W2176471040 hasConceptScore W2176471040C126322002 @default.
• W2176471040 hasConceptScore W2176471040C142462285 @default.
• W2176471040 hasConceptScore W2176471040C159654299 @default.
• W2176471040 hasConceptScore W2176471040C177713679 @default.
• W2176471040 hasConceptScore W2176471040C203014093 @default.
• W2176471040 hasConceptScore W2176471040C2522874641 @default.
• W2176471040 hasConceptScore W2176471040C2776525042 @default.
• W2176471040 hasConceptScore W2176471040C2777691041 @default.
• W2176471040 hasConceptScore W2176471040C2779134260 @default.

• next